Gilead and GSK go head-to-head with similar HIV drug data

(Reuters) – Gilead Sciences Inc and GlaxoSmithKline Plc will go head-to-head with rival versions of an improved class of HIV medicines, after clinical studies showed the U.S. company’s new drug bictegravir was as effective as GSK’s product.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *